IRMD Valuation

IRadimed Corp

Add to Watchlist

Advanced Chart

70.710

+0.19(0.269%)1D

Overview
Forecast
Valuation
Earnings

IRMD Relative Valuation

IRMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IRMD is overvalued; if below, it's undervalued.

Historical Valuation

IRadimed Corp (IRMD) is now in the Fair zone, suggesting that its current forward PE ratio of 41.59 is considered Fairly compared with the five-year average of 38.37. The fair price of IRadimed Corp (IRMD) is between 46.50 to 75.21 according to relative valuation methord.

Relative Value

Fair Zone

46.50-75.21

Current Price：70.71

Fair

41.59

Trailing

Forward

0.00

EV/EBITDA

IRadimed Corp. (IRMD) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

32.39

EV/EBIT

IRadimed Corp. (IRMD) has a current EV/EBIT of 32.39. The 5-year average EV/EBIT is 27.31. The thresholds are as follows: Strongly Undervalued below 14.34, Undervalued between 14.34 and 20.82, Fairly Valued between 33.79 and 20.82, Overvalued between 33.79 and 40.28, and Strongly Overvalued above 40.28. The current Forward EV/EBIT of 32.39 falls within the Historic Trend Line -Fairly Valued range.

10.65

IRadimed Corp. (IRMD) has a current PS of 10.65. The 5-year average PS is 8.35. The thresholds are as follows: Strongly Undervalued below 5.43, Undervalued between 5.43 and 6.89, Fairly Valued between 9.81 and 6.89, Overvalued between 9.81 and 11.27, and Strongly Overvalued above 11.27. The current Forward PS of 10.65 falls within the Overvalued range.

0.00

P/OCF

IRadimed Corp. (IRMD) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

IRadimed Corp. (IRMD) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

IRadimed Corp (IRMD) has a current Price-to-Book (P/B) ratio of 9.54. Compared to its 3-year average P/B ratio of 7.57 , the current P/B ratio is approximately 25.96% higher. Relative to its 5-year average P/B ratio of 7.06, the current P/B ratio is about 35.16% higher. IRadimed Corp (IRMD) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.92%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 1.97% , the current FCF yield is about -100.00% lower.

9.54

P/B

Median3y

7.57

Median5y

7.06

1.58

FCF Yield

Median3y

1.92

Median5y

1.97

Competitors Valuation Multiple

The average P/S ratio for IRMD's competitors is , providing a benchmark for relative valuation. IRadimed Corp Corp (IRMD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 13.84%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Tandem Diabetes Care Inc

Performance Decomposition

Market capitalization of IRMD increased by 40.60% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 35.63 to 43.92.

The secondary factor is the Revenue Growth, contributed 13.84%to the performance.

Overall, the performance of IRMD in the past 1 year is driven by P/E Change. Which is more unsustainable.

13.84%

17.93M → 20.41M

Revenue Growth

3.47%

27.34 → 28.29

Margin Expansion

23.29%

35.63 → 43.92

P/E Change

40.60%